Previous 10 | Next 10 |
MONTREAL, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced that management will host a conference call in conjunctio...
The FDA has granted Rare Pediatric Disease designationto Clementia Pharmaceuticals' ( CMTA +6% ) palovarotene for the treatment of fibrodysplasia ossificans progressiva (FOP). More news on: Clementia Pharmaceuticals, Read more ...
MONTREAL, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced that the U.S. Food and Drug Administration (FDA) has gran...
Clementia Pharmaceuticals (NASDAQ: CMTA ): Q3 GAAP EPS of -$0.46. More news on: Clementia Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, Read more ...
Recent FDA Meeting Identifies Path Towards NDA Submission in the Second Half of 2019 Financing Raises $75 million to Support a Potential Commercial Launch MONTREAL, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ: CMTA), a clinical-stage biopharmaceutical...
Clementia Pharmaceuticals Inc. (NASDAQ: CMTA ) has priced public offering of 5.3M common shares at $13.25 per share, for estimated gross proceeds of $70.2M. More news on: Clementia Pharmaceuticals, Healthcare stocks news, Read more ...
MONTREAL, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced the pricing of an underwritten public offering of 5,3...
MONTREAL, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced that it intends to offer and sell, subject to market ...
NEW YORK, Oct. 29, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Insys Therapeutics, Inc. (NASDAQ:INSY), Achaogen, Inc. (NASDAQ:AKAO), ...
October 25, 2018 Palm Beach, FL – (October 25, 2018) – Cancer has a major impact on the health and well being of individuals across the globe. Cancer is identified as one of the leading causes of death worldwide. In 2017, approximately 0.5% of the world’s population ...
News, Short Squeeze, Breakout and More Instantly...
Clementia Pharmaceuticals Inc. Company Name:
CMTA Stock Symbol:
NASDAQ Market:
Clementia Pharmaceuticals Inc. Website:
TORONTO, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”),...
MONTREAL, April 11, 2019 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA) ("Clementia" or the "Corporation") is pleased to announce that the Québec Superior Court issued earlier today a final order approving the previously announced statutory plan of arrangement u...
MONTREAL, April 09, 2019 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA) ("Clementia" or the "Corporation") is pleased to announce that its shareholders have approved the previously announced statutory plan of arrangement under the Canada Business Corporations Act ...